You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • OP0213 Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow Up at 34 Months

Article info

Article menu
Download PDFPDF
Oral Presentations
Abstract session: Novel advances in vasculitis: pathogenesis, diagnosis and treatment
OP0213 Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow Up at 34 Months

Authors

Citation

Terrier B, Pagnoux C, Karras A, et al
OP0213 Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow Up at 34 Months
Annals of the Rheumatic Diseases 2013;72:A124.

Publication history

  • First published January 23, 2014.
Online issue publication 
November 28, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions